Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Major breakthrough in TB diagnosis
DNA
Scientists used genome techonology to isolate different strains of TB.
Scientists use genome sequencing to isolate strains of TB

Researchers in the UK have made a world-first breakthrough in the diagnosis of tuberculosis (TB).

According to BBC News, scientists at the Universities of Oxford and Birmingham have managed to isolate different strains of the disease using genome sequencing.

This means that patients will receive a diagnosis much faster, instead of waiting months for treatment.

Health secretary Jeremy Hunt said that the breakthrough "will save lives".

While incidents of TB in the UK have fallen in recent years, there are still some 6,000 cases reported each year. 

The illness is associated with health inequality, affecting people in deprived communities seven times more than people in the least deprived areas.

Scientists say they can identify the DNA strains in different samples in less than a week. As well as allowing patients to begin recovery sooner, this will also reduce the chance of infection spreading.

“We’re able to provide information on the species of organism and the drugs to which it may be resistant if it’s TB,” explained consultant microbiologist Dr Grace Smith.

This is the first time anyone in the world has applied genome technology on such a large scale, according to Public Health England.

The announcement comes as a new study shows that efforts to control the disease could be severely hampered by the rise in drug-resistant bacteria.

Published in The Lancet, the study found that one in five global cases of the disease is now resistant to at least one major treatment drug.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.